Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 26, 2016OncotargetOpen Access

Higher serum IGFBP2 level (> 400.01 ng/ml) was an independent prognostic factor predicting worse overall survival in patients with gastric cancer (HR 3.749, P=0.034).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does preoperative serum IGFBP2 level predict overall survival in patients with gastric cancer?

Population

118 gastric cancer patients and 34 healthy controls

Comparison

Preoperative serum insulin-like growth… vs Healthy controls and lower IGFBP2 levels

Design

Cohort

Key result

Higher serum IGFBP2 level (> 400.01 ng/ml) was an independent prognostic factor predicting worse overall survival in patients with gastric cancer (HR 3.749, P=0.034).

Authors

HHHoon HurEYEun Ji YuIHIn‐Hye Ham

Discussion

Loading...

Member takes

Overview

May aid preoperative risk stratification in gastric cancer; hypothesis-generating pending prospective validation.

Study Design

Type

Observational (n=152)

Structured PICO

Does preoperative serum IGFBP2 level predict overall survival in patients with gastric cancer?

P
Population
152 participants including 118 gastric cancer patients and 34 healthy controls evaluated for the prognostic value of serum IGFBP2 levels.
E
Exposure
Preoperative serum insulin-like growth factor-binding protein 2 (IGFBP2) measurement
C
Comparator
Healthy controls (for baseline levels) and lower IGFBP2 levels (for survival analysis)
O
Outcome
Overall survivalhard clinical

Main Result

Hazard Ratio: 3.749

p-value: p=0.034

Preoperative serum IGFBP2 levels are elevated in gastric cancer patients and higher levels independently predict worse overall survival.

Cite This Study

Hur et al. (2016) conducted an observational in Gastric cancer (n=152). Higher serum IGFBP2 level (> 400.01 ng/ml) vs. Lower serum IGFBP2 level was evaluated on Overall survival (HR 3.749, p=0.034). Higher serum IGFBP2 level (> 400.01 ng/ml) was an independent prognostic factor predicting worse overall survival in patients with gastric cancer (HR 3.749, P=0.034).

synapsesocial.com/papers/6a95c18ec992b03bd554fcebhttps://doi.org/10.18632/oncotarget.14202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Serum and tissue IGFBP2 as a prognostic biomarker in gastric adenocarcinoma: A multi-cohort clinical validation study2026 · 1 citations
  2. 2Impact of Insulin-like Growth Factor System on the Progression and Survival of Gastric Adenocarcinoma2024
  3. 3Comprehensive Analysis of IGFBPs as Biomarkers in Gastric Cancer2021 · 32 citations
  4. 4IGF Pathway Components as Potential Biomarkers in Gastric Cancer2025
  5. 5Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer2000 · 113 citations